Insight Molecular Diagnostics Inc. — Director's Dealing 2016

Feb 18, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2016-02-16

Reporting Person: WEST MICHAEL D (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-02-16	Option to Purchase Common Stock	$3.06	A	60000	Acquired	2026-02-15	Common Stock (60000)	Indirect

Footnotes

F1: One quarter of the options granted to Karen Chapman shall vest on February 15, 2017, subject to the completion of 12 months of continuous employment from the date of grant, and the balance shall vest in 36 monthly installments upon the completion of each month of continuous employment from the first anniversary of the date of grant. Dr. West and Dr. Chapman are husband and wife.